Infliximab Drug Market Size, Share, Growth, Trends 2024-2032

The growth of the global infliximab drug market is driven by the rising number of rheumatoid arthritis cases, which was close to 35.35 million in 2023. The prevalence of rheumatoid arthritis disease is likely to grow at a CAGR of 1.3% in the forecast period of 2024-2032 and the number of cases is likely to reach nearly 39.54 million by 2032.

全球抗TNF-α单克隆抗体药物市场之增长，得益于类风湿性关节炎病例数的不断攀升，2023年该病例数已接近3535万。预计在2024年至2032年的预测期内，类风湿性关节炎的患病率将保持1.3%的复合年增长率，病例数预计将在2032年达到近3954万。